ADX 629
Alternative Names: ADX-629Latest Information Update: 04 Nov 2025
At a glance
- Originator Aldeyra Therapeutics
- Class Anti-inflammatories; Antiallergics; Antipsoriatics; Antitussives; Antivirals; Hepatoprotectants; Skin disorder therapies; Small molecules
- Mechanism of Action Aldehyde inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alcoholic hepatitis; Alcoholism; Allergic asthma; Atopic dermatitis; Cough; Cytokine release syndrome; Lipoid nephrosis; Nephrotic syndrome; Plaque psoriasis; SARS-CoV-2 acute respiratory disease; Sjogren-Larsson syndrome
Most Recent Events
- 04 Nov 2025 Discontinued - Phase-I/II for Sjogren-Larsson syndrome in USA (PO)
- 04 Nov 2025 Discontinued - Phase-II for Alcoholic hepatitis (In adults, In the elderly) in USA (PO)
- 04 Nov 2025 Discontinued - Phase-II for Alcoholism in USA (PO)